Release Date: 23-Jan-2025
UBB-2048 is an investigational bispecific antibody developed by Unity Biotechnology, designed to address retinal vascular diseases by targeting two critical components involved in pathological blood vessel formation. It is a fully human IgG1-kappa antibody, specifically engineered with Fc mutations that disable FcgR binding, allowing for a more targeted therapeutic effect. The antibody simultaneously targets the Tie2 receptor and vascular endothelial growth factor (VEGF), two key players in the regulation of blood vessel growth and function. This dual-action approach aims to inhibit pathological neovascularization while promoting the restoration of healthy vasculature, an essential aspect in treating various retinal diseases.
Download Report: https://www.kuickresearch.com/ccformF.php?t=1737625307
The mechanism of action of UBB-2048 focuses on the inhibition of VEGF, a protein that stimulates abnormal blood vessel formation, or neovascularization, in conditions like diabetic macular oedema and age-related macular degeneration (AMD). In these diseases, uncontrolled angiogenesis leads to vision impairment due to the growth of fragile and leaky blood vessels in the retina. By neutralizing VEGF, UBB-2048 reduces this aberrant blood vessel growth, thereby addressing the root cause of the disease. Additionally, by activating the Tie2 receptor, UBB-2048 helps to stabilize and restore the function of healthy blood vessels in the retina, further contributing to the therapeutic effect.
The unique design of UBB-2048 as a bispecific antibody enhances its potential to simultaneously target two critical pathways involved in retinal vascular diseases, offering a more comprehensive treatment approach. This could provide significant clinical benefits over current therapies that often target VEGF alone. UBB-2048 is currently undergoing Phase II clinical trials for retinal disorders, where its ability to effectively treat diseases like diabetic macular oedema and age-related macular degeneration is being closely evaluated. If successful, UBB-2048 could represent a significant advancement in the treatment of these debilitating conditions, improving both vision and quality of life for patients.